Y Intercept Hong Kong Ltd Makes New Investment in Immunome, Inc. $IMNM

Y Intercept Hong Kong Ltd purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 85,227 shares of the company’s stock, valued at approximately $793,000. Y Intercept Hong Kong Ltd owned 0.10% of Immunome as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Teacher Retirement System of Texas raised its holdings in Immunome by 49.0% in the 1st quarter. Teacher Retirement System of Texas now owns 17,360 shares of the company’s stock worth $117,000 after purchasing an additional 5,712 shares during the period. Bank of New York Mellon Corp lifted its stake in Immunome by 56.8% during the first quarter. Bank of New York Mellon Corp now owns 193,147 shares of the company’s stock worth $1,300,000 after purchasing an additional 69,944 shares in the last quarter. Alps Advisors Inc. raised its stake in shares of Immunome by 23.9% in the first quarter. Alps Advisors Inc. now owns 62,544 shares of the company’s stock valued at $421,000 after acquiring an additional 12,074 shares in the last quarter. Arizona State Retirement System increased its holdings in Immunome by 66.2% in the first quarter. Arizona State Retirement System now owns 18,764 shares of the company’s stock valued at $126,000 after buying an additional 7,476 shares during the last quarter. Finally, Private Capital Advisors Inc. purchased a new position in Immunome in the first quarter valued at $259,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on IMNM. Guggenheim reissued a “buy” rating and issued a $25.00 target price on shares of Immunome in a report on Monday, August 25th. The Goldman Sachs Group assumed coverage on Immunome in a research report on Monday, September 22nd. They issued a “buy” rating and a $26.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Evercore ISI assumed coverage on shares of Immunome in a research report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price target for the company. Finally, Craig Hallum initiated coverage on Immunome in a research report on Friday, September 5th. They set a “buy” rating and a $26.00 price objective for the company. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.20.

Immunome Price Performance

Shares of IMNM stock opened at $15.35 on Thursday. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $17.87. The firm has a market capitalization of $1.34 billion, a P/E ratio of -4.98 and a beta of 1.96. The company’s fifty day moving average price is $12.60 and its two-hundred day moving average price is $10.39.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.02. The firm had revenue of $4.02 million for the quarter, compared to analyst estimates of $1.03 million. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. On average, sell-side analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.